Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Alleges Rivals Of Meddling With Daiichi Sankyo Deal; U.S. House Committee Enters Fray

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - India's leading drug maker Ranbaxy Laboratories has alleged that global big pharma players are trying to scuttle its acquisition by Daiichi Sankyo. U.S. FDA and the U.S. Department of Justice's probe of Ranbaxy is part of a larger battle against the company, CEO Malvinder Singh said in a television interview on Friday, indicating that vested interests in the global industry were trying to stall the deal
Advertisement

Related Content

Ranbaxy CEO Malvinder Singh On U.S. FDA’s Investigation And The Daiichi Sankyo Deal: An Interview With PharmAsia News
Ranbaxy CEO Malvinder Singh On U.S. FDA’s Investigation And The Daiichi Sankyo Deal: An Interview With PharmAsia News
Ranbaxy Sees Light At The End Of DoJ Investigation Tunnel - CEO Interview
Ranbaxy Sees Light At The End Of DoJ Investigation Tunnel - CEO Interview
U.S. FDA To Open Offices In China As Early As September; India Next
U.S. FDA To Open Offices In China As Early As September; India Next
Indian Generic Group Tells New Department Of Pharmaceuticals That Industry Is Under Attack By Multinationals
Ranbaxy Denies Fraudulent Conduct Alleged By U.S. FDA As Rumors Swirl About Daiichi Deal
Ranbaxy Denies Fraudulent Conduct Alleged By U.S. FDA As Rumors Swirl About Daiichi Deal
Ranbaxy Will Produce Internal Audits To U.S. DOJ But Warns Of Impact To Industry From "Bad Policy"
Advertisement
UsernamePublicRestriction

Register

SC069035

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel